Abstract
Introduction: Systemic Lupus Erythematosus (SLE) is adisease primarily affecting women in their child-bearing years. SLE can affect any component of the respiratory system and manifest with pleuritis (with or without effusion), interstitial lung disease (ILD), alveolar hemorrhage, diaphragmatic weakness, pulmonary hypertension, airways disease, or pulmonary embolism. ILD occurs with a lower frequency in SLE compared with other connective tissue disease (CTD) subtypes. It is not known whether SLE-ILD differs from ILD in other CTD subtypes.
Aim of the work: estimate the possible relationship between interstitial lung diseases and different antinuclear antibodies among patients with systemic lupus erythematosus.
Patients and Methods: Cross sectional clinical study. A total of 100 SLE patients attending to Sohag University Hospitals will be included in the study. Patients included in this study will be classified as SLE patients according to either the 2012 SLICC criteria or the new 2017 ACR/EULAR SLE classification criteria.
Results: ANA (antinuclear antibody) positivity, chest manifestations like (cough, dyspnea, expectoration, fever&hemoptysis) are predictive variates for SLE-ILD.
Conclusion: We observed a population of SLE-ILD and concluded that ANA (antinuclear antibody) positivity, chest manifestations like (cough, dyspnea, expectoration, fever&hemoptysis) are predictive variates for SLE-ILD. Also ANAIF speckled pattern has specificity to SLE-ILD and AntiSS-A/Ro52KD antibody is more specific to SLE-ILD. We recom‌mend HRCT and PFT scan in these SLE patients.